High Plasma sRAGE (Soluble Receptor for Advanced Glycation End Products) Is Associated With Slower Carotid Intima-Media Thickness Progression and Lower Risk for First-Time Coronary Events and Mortality
Key result
Higher baseline sRAGE levels were associated with a decreased risk for major adverse coronary events (HR 0.90; 95% CI 0.82-0.97; P=0.009) and mortality over 21 years.
Why the study?
Animal studies showed sRAGE has atheroprotective properties, but whether sRAGE and sEMMPRIN are associated with vascular disease progression, incident coronary events, and mortality in humans was unknown.
Are baseline sRAGE and sEMMPRIN levels associated with vascular disease progression, incident coronary events, and mortality in cardiovascular disease-free individuals?
Population
4612 cardiovascular disease-free individuals from the Malmö Diet and Cancer cohort
Comparison
Baseline plasma sRAGE and sEMMPRIN levels
Design
Population-based cohort study
Follow-up
Median 16.5 years for carotid IMT, 21 years for clinical events
Authors
Discussion
Loading...
Member takes
Implication
Hypothesis-generating for sRAGE as coronary risk biomarker; prospective studies needed before clinical adoption.
Study Design
Type
Cohort (n=4,612)
Structured PICO
Are baseline sRAGE and sEMMPRIN levels associated with vascular disease progression, incident coronary events, and mortality in cardiovascular disease-free individuals?
P
Population
4,612 cardiovascular disease-free individuals from a population-based cohort, followed for up to 21 years.
E
Exposure
Baseline sRAGE (soluble receptor for advanced glycation end products) and sEMMPRIN (soluble extracellular matrix metalloproteinase inducer) levels
O
Outcome
Carotid intima-media thickness progression, incident major adverse coronary events, and mortalityhard clinical
Main Result
Hazard Ratio: 0.9 (95% CI 0.82–0.97)
p-value: p=0.009
Higher baseline sRAGE levels are independently associated with slower carotid intima-media thickness progression and a lower risk of incident coronary events and mortality in individuals without baseline cardiovascular disease.
Limitations
- Predictive value was too weak to promote sRAGE as a useful clinical biomarker in the population
- predictive value was too weak to promote sRAGE as a useful clinical biomarker in the population
Cite This Study
Larsen et al. (2019) conducted a cohort in Cardiovascular disease-free (n=4,612). Baseline sRAGE (Soluble Receptor for Advanced Glycation End Products) was evaluated on Major adverse coronary events (HR 0.90, 95% CI 0.82-0.97, p=0.009). Higher baseline sRAGE levels were associated with a decreased risk for major adverse coronary events (HR 0.90; 95% CI 0.82-0.97; P=0.009) and mortality over 21 years.